SCHEMBL5234064

SCHEMBL5234064

COCCNS(=O)(=O)c1ccc(-c2nc3c(c(-c4ccccc4)nn3C)c(=O)[nH]2)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
POLB P06746 1/20 0.42
PKM P14618 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
PDE5A O76074 14/20 0.42
PDE7A Q13946 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
PDE2A O00408 1/20 0.39
PDE9A O76083 1/20 0.39
PDE4A P27815 1/20 0.39
PDE6C P51160 1/20 0.39
PDE1A P54750 1/20 0.39
PDE11A Q9HCR9 1/20 0.39
PDE10A Q9Y233 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5228572 0.93 PDE7A (0.42) PDE5APDE7AMAPTPDE2APDE9A
SCHEMBL5231272 0.91 PDE5A (0.48) ALDH1A1PDE5APDE7AMAPTPDE2A
SCHEMBL5231390 0.91 PDE5A (0.44) PDE5APDE7AMAPT
SCHEMBL5227715 0.88 PDE7A (0.45) ALDH1A1PDE5APDE7A
SCHEMBL5229312 0.85 PDE7A (0.47) PDE5APDE7A
SCHEMBL5234058 0.82 PDE7A (0.66) MEN1ALDH1A1POLBPKMTSHR
SCHEMBL5231816 0.81 PDE5A (0.48) PDE5APDE7A
SCHEMBL5238219 0.81 PDE7A (0.42) ALDH1A1PDE5APDE7ANPSR1MAPT
SCHEMBL5228423 0.81 ALDH1A1 (0.47) MEN1ALDH1A1POLBKMT2APDE5A
SCHEMBL5231363 0.80 PDE5A (0.55) PDE5APDE7ALMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1454897-B1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY ASUBIO PHARMA CO LTD (JP) 2007-10-10 EP disclosed
US-7268128-B2 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action AUSBIO PHARMA CO., LTD. (JP) 2007-09-11 US disclosed
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action OMEROS CORPORATION 2005-07-07 US disclosed
EP-1454897-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY Daiichi Suntory Pharma Co., Ltd. (JP) 2004-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148604-A1 Pyrazolopyrimidinone derivatives having PDE7 inhibiting action PDE7B, PDE3B, PDE3A MEN1 4100/4885ALDH1A1 711/4885POLB 2355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.